AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone41-21-345-9121
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$7.36 million
Profitability
Miscellaneous
Employees92
Next Earnings Date11/12/2019 (Estimated)
OptionableNot Optionable
AC Immune (NASDAQ:ACIU) Frequently Asked Questions
What is AC Immune's stock symbol?
AC Immune trades on the NASDAQ under the ticker symbol "ACIU."
How were AC Immune's earnings last quarter?
AC Immune SA (NASDAQ:ACIU) announced its earnings results on Wednesday, August, 14th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.24) by $0.01. The company had revenue of $1.51 million for the quarter, compared to analyst estimates of $8.49 million. AC Immune had a return on equity of 7.64% and a net margin of 22.92%. View AC Immune's Earnings History.
When is AC Immune's next earnings date?
What price target have analysts set for ACIU?
3 analysts have issued 1-year price targets for AC Immune's shares. Their predictions range from $8.00 to $18.00. On average, they anticipate AC Immune's share price to reach $14.00 in the next twelve months. This suggests a possible upside of 187.5% from the stock's current price. View Analyst Price Targets for AC Immune.
What is the consensus analysts' recommendation for AC Immune?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AC Immune in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for AC Immune.
What are Wall Street analysts saying about AC Immune stock?
Here are some recent quotes from research analysts about AC Immune stock:
- 1. According to Zacks Investment Research, "AC Immune SA is a biopharmaceutical company. It develops, discover and design novel, proprietary medicines for prevention, diagnosis and treatment of neurodegenerative diseases. The Company's pipeline includes Crenezumab, ACI-24, Anti-Tau antibody, Morphomer Tau, Tau-PET imaging agent, Morphomer Abeta and Morphomer alpha-syn which are in clinical trial. AC Immune SA is based in Lausanne, Switzerland. " (4/8/2019)
- 2. HC Wainwright analysts commented, "We hosted a management breakfast (January 9, 2019) in the JPM (JPM; not rated) healthcare conference with AC Immune’s CEO, Andrea Pfeifer. During the discussions with management, a key focus from investors was on the interim analysis of crenezumab’s CREAD1 Phase 3 trial this year, and the role of effector function in targeting mis-folded proteins in the brain. We have limited clarity on the timing or the type of crenezumab’s interim analysis based on the conversations with management, and believe that this event remains a critical inflection point for the company. We think that the updated BAN2401 and aducanumab data collectively lend support to amyloid hypothesis and should have positive read-through to crenezumab." (1/24/2019)
Has AC Immune been receiving favorable news coverage?
Media headlines about ACIU stock have trended negative on Monday, InfoTrie reports. The research group identifies positive and negative news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. AC Immune earned a news sentiment score of -2.6 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for AC Immune.
Are investors shorting AC Immune?
AC Immune saw a drop in short interest during the month of September. As of September 30th, there was short interest totalling 391,100 shares, a drop of 22.0% from the August 30th total of 501,700 shares. Based on an average trading volume of 103,000 shares, the short-interest ratio is presently 3.8 days. Approximately 1.2% of the shares of the stock are sold short. View AC Immune's Current Options Chain.
Who are some of AC Immune's key competitors?
Some companies that are related to AC Immune include Nabriva Therapeutics (NBRV), Opko Health (OPK), BELLUS Health (BLUSF), Turning Point Therapeutics (TPTX), Enanta Pharmaceuticals (ENTA), Radius Health (RDUS), Innoviva (INVA), Zymeworks (ZYME), ArQule (ARQL), Theravance Biopharma (TBPH), Esperion Therapeutics (ESPR), Gossamer Bio (GOSS), Dicerna Pharmaceuticals (DRNA), AnaptysBio (ANAB) and TherapeuticsMD (TXMD).
What other stocks do shareholders of AC Immune own?
Who are AC Immune's key executives?
AC Immune's management team includes the folowing people:
- Dr. Andrea Pfeifer, Co-Founder, CEO & Director (Age 61)
- Mr. Joerg Hornstein, Chief Financial Officer (Age 41)
- Mr. Piergiorgio Donati, Head of Technical Operations & Program Management (Age 48)
- Dr. Marie Kosco-Vilbois, Chief Scientific Officer (Age 61)
- Mr. Jean-Fabien Monin, Chief Admin. Officer (Age 48)
When did AC Immune IPO?
(ACIU) raised $55 million in an initial public offering (IPO) on Friday, September 23rd 2016. The company issued 4,600,000 shares at $11.00-$13.00 per share. Credit Suisse, Jefferies and Leerink Partners served as the underwriters for the IPO.
How do I buy shares of AC Immune?
Shares of ACIU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is AC Immune's stock price today?
One share of ACIU stock can currently be purchased for approximately $4.87.
How big of a company is AC Immune?
AC Immune has a market capitalization of $329.02 million and generates $7.36 million in revenue each year. The company earns $-52,090,000.00 in net income (profit) each year or ($0.82) on an earnings per share basis. AC Immune employs 92 workers across the globe.View Additional Information About AC Immune.
What is AC Immune's official website?
How can I contact AC Immune?
AC Immune's mailing address is EPFL Innovation Park Building B, Lausanne V8, 1015. The company can be reached via phone at 41-21-345-9121 or via email at [email protected]
MarketBeat Community Rating for AC Immune (NASDAQ ACIU)
MarketBeat's community ratings are surveys of what our community members think about AC Immune and other stocks. Vote "Outperform" if you believe ACIU will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACIU will underperform the S&P 500 over the long term. You may vote once every thirty days.
